Drugs & TargetsFree FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA advisory committee to vote on GRAIL’s multi-cancer detection test, Galleri August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA approves companion diagnostic supporting patients with advanced melanoma August 14, 2026Vol.52 No.32
Drugs & Targets After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug July 31, 2026Vol.52 No.30
Drugs & Targets EMA CHMP recommends approval for biosimilar Denosumab Ascend and Nylaspeg, recommends against Tacquell July 31, 2026Vol.52 No.30
Drugs & Targets FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer July 24, 2026Vol.52 No.29
Drugs & Targets FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer July 24, 2026Vol.52 No.29
Drugs & Targets EMA approves phase III clinical study of Alpha1H bladder cancer therapy July 24, 2026Vol.52 No.29
Drugs & Targets FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility July 17, 2026Vol.52 No.28
